论文部分内容阅读
目的探讨恩替卡韦联合胸腺肽a1治疗慢性乙型肝炎的临床效果及安全性。方法将2011年8月至2012年7月收治的慢性乙型肝炎患者120例随机分为两组,对照组60例单用恩替卡韦口服治疗,研究组60例在对照组用药基础上加用注射用胸腺肽a1皮下注射。比较两组疗效和不良反应。结果研究组治疗总有效率为90.0%,对照组为53.3%,两组比较差异有统计学意义(P<0.01)。结论在抗病毒治疗过程中,加用免疫调节用药可进一步提高疗效,联合应用恩替卡韦和胸腺肽a1治疗慢性乙型肝炎具有较好的有效性和安全性。
Objective To investigate the clinical efficacy and safety of entecavir combined with thymosin a1 in the treatment of chronic hepatitis B patients. Methods 120 patients with chronic hepatitis B who were admitted from August 2011 to July 2012 were randomly divided into two groups. 60 patients in the control group were treated with entecavir alone. The study group consisted of 60 patients in the control group received injection Thymosin a1 subcutaneous injection. The efficacy and adverse reactions of the two groups were compared. Results The total effective rate was 90.0% in the study group and 53.3% in the control group, with significant difference between the two groups (P <0.01). Conclusion In the course of antiviral therapy, adding immunomodulatory drugs can further improve the curative effect, and the combined application of entecavir and thymosin a1 has good efficacy and safety in the treatment of chronic hepatitis B.